E
Shares of Spark Therapeutics (ONCE) ended the day up 25% after reporting positive phase 3 results in patients with rare blindness. More specifically these patients have a rare blindness that is caused by the RPE65 gene — also known as inherited retinal dystrophies. The company uses its gene therapy drug known as SPK-RPE65 to restore…